Ganymed's IMAB027 Enters Phase I/II Clinical Trial for Ovarian Cancer
Ganymed Pharmaceuticals AG announced today that the first patients are being enrolled and are starting treatment in a Ph…
Ganymed Pharmaceuticals AG announced today that the first patients are being enrolled and are starting treatment in a Ph…
Ganymed Pharmaceuticals AG, a biopharmaceutical company developing highly selective Ideal Monoclonal Antibodies (IMABs)…